Finance

Lists
Q3 2026 earnings • released • EPS beat +7,77% • Revenue beat +2,93%
See results
GH:NASDAQ
Guardant Health Inc
155,35 $
-2,17%
(-3,44) 1D
155,57 $
+0,14% (+0,22)
After hours
Closed: 10 қар., 16:00:01 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GH...
Open
158,71 $
High
160,94 $
Low
153,00 $
Mkt. cap
21,02 млрд
Avg. vol.
2,06 млн
Volume
2,41 млн
52-wk high
191,01 $
52-wk low
74,55 $
EPS
-3,68 $
Beta
1,67
Shares outstanding
135,29 млн
No. of employees
2 мың
Open
158,71 $
High
160,94 $
Low
153,00 $
Mkt. cap
21,02 млрд
Avg. vol.
2,06 млн
Volume
2,41 млн
52-wk high
191,01 $
52-wk low
74,55 $
EPS
-3,68 $
Beta
1,67
Shares outstanding
135,29 млн
No. of employees
2 мың
News stories
From web sources and news partners
Profile
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers. Wikipedia
About Guardant Health Inc
CEOHelmy Eltoukhy | AmirAli Talasaz
Employees2,5 мың
Founded2012
HeadquartersПало Альто, Калифорния, Америка Құрама Штаттары
SectorHealth Care
IndustryHealth care provider
Websiteguardanthealth.com
Analyst ratings
Based on 19 analysts giving stock ratings to GH in the past 3 months
Strong buy
Buy
19
Hold
0
Sell
0
12-month forecast
Based on 19 Wall Street analysts offering 12 month price targets for GH in the last 3 months.
Highest
Current 155,35 $
225,00 $ (+44,83%)
Average
204,00 $ (+31,32%)
Lowest
180,00 $ (+15,87%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Westenberg
Piper Sandler
Buy
Reiterated
190,00 $
+22,3%
11/10/2026
Lu Li
Bank of America Securities
Buy
Maintained
-
-
11/06/2026
Daniel Arias
Stifel Nicolaus
Buy
Maintained
180,00 $
+15,9%
11/06/2026
Evie Koslosky
Goldman Sachs
Buy
Maintained
210,00 $
+35,2%
11/06/2026
Kyle Mikson CFA
Canaccord Genuity
Buy
Reiterated
205,00 $
+32%
11/06/2026
Dan Leonard
RBC Capital
Buy
Maintained
200,00 $
+28,7%
11/06/2026
Daniel Brennan
TD Cowen
Buy
Maintained
220,00 $
+41,6%
11/06/2026
Catherine Ramsey Schulte
Robert W. Baird
Buy
Maintained
196,00 $
+26,2%
11/06/2026
Luke Sergott
Barclays
Buy
Maintained
220,00 $
+41,6%
11/06/2026
Mark Massaro
BTIG
Buy
Maintained
210,00 $
+35,2%
10/27/2026
Max Masucci
Roth MKM
Buy
Initiated
200,00 $
+28,7%
10/22/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Maintained
200,00 $
+28,7%
10/20/2026
Eve Burstein
Bernstein
Buy
Reiterated
210,00 $
+35,2%
10/19/2026
Casey Woodring
J.P. Morgan
Buy
Maintained
195,00 $
+25,5%
10/14/2026
Michael Ryskin
Bank of America Securities
Buy
Maintained
200,00 $
+28,7%
10/09/2026
Subbu Nambi
Guggenheim
Buy
Maintained
200,00 $
+28,7%
10/01/2026
William Bonello
Craig-Hallum
Buy
Maintained
-
-
09/15/2026
Unknown Analyst
UBS
Buy
Maintained
225,00 $
+44,8%
09/09/2026
Doug Schenkel
UBS
Buy
Maintained
225,00 $
+44,8%
09/09/2026
Jamie Clark
Rothschild & Co Redburn
Buy
Initiated
203,00 $
+30,7%
09/08/2026
Matt Larew
William Blair
Buy
Maintained
-
-
09/08/2026
Bradley Bowers
Mizuho Securities
Buy
Maintained
200,00 $
+28,7%
08/04/2026
Mason Carrico
Stephens
Buy
Maintained
195,00 $
+25,5%
08/04/2026
Brandon Couillard
Wells Fargo
Buy
Maintained
125,00 $
-19,5%
07/29/2026
Patrick B Donnelly
Citi
Buy
Maintained
215,00 $
+38,4%
07/08/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
200,00 $
+28,7%
07/06/2026
Puneet Souda
Leerink Partners
Buy
Reiterated
-
-
06/02/2026
Paige Chamberlain‏
Wolfe Research
Buy
Reiterated
150,00 $
-3,4%
06/01/2026
Unknown Analyst
Wolfe Research
Buy
Reiterated
150,00 $
-3,4%
06/01/2026
Andrew Brackmann
William Blair
Buy
Maintained
-
-
05/27/2026
Andrew Cooper
Raymond James
Buy
Reiterated
129,00 $
-17%
02/23/2026
Last report
2026 ж. 05 қар.
Fiscal period
Q3 2026
-0,29 $ / -0,31 $
+7,77%beat
Revenue / Est. (USD)
360,98 млн / 350,71 млн
+2,93%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
2026 ж. қыр.
Revenue
281,27 млн
301,66 млн
334,98 млн
360,98 млн
Cost of goods sold
99,49 млн
104,92 млн
115,95 млн
124,82 млн
Cost of revenue
99,49 млн
104,92 млн
115,95 млн
124,82 млн
Research and development expenses
98,26 млн
91,04 млн
96,53 млн
100,84 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
204,20 млн
227,06 млн
250,61 млн
269,08 млн
Operating expense
302,46 млн
318,10 млн
347,15 млн
369,92 млн
Total operating expenses
401,96 млн
423,02 млн
463,10 млн
494,74 млн
Operating income
-120,69 млн
-121,35 млн
-128,12 млн
-133,76 млн
Other non operating income
-4,69 млн
1,55 млн
308,00 м.
342,00 м.
EBT including unusual items
-130,22 млн
-111,70 млн
-119,96 млн
-124,02 млн
EBT excluding unusual items
-116,52 млн
-111,70 млн
-118,96 млн
-125,02 млн
Income tax expense
-1,73 млн
372,00 м.
185,00 м.
343,00 м.
Effective tax rate
1,33%
-0,33%
-0,15%
-0,28%
Other operating expenses
-
-
-
-
Net income
-128,49 млн
-112,08 млн
-120,14 млн
-124,36 млн
Net profit margin
-45,68%
-37,15%
-35,87%
-34,45%
Earnings per share
-0,50
-0,45
-0,42
-0,29
Interest and investment income
10,03 млн
11,15 млн
10,20 млн
9,75 млн
Interest expense
-1,18 млн
-3,05 млн
-1,35 млн
-1,34 млн
Net interest expenses
8,85 млн
8,10 млн
8,85 млн
8,40 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-110,64 млн
-111,91 млн
-118,56 млн
-123,59 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google қолданбалары